Drug Trial Radar · NCT04906434
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 26, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase 1 study with an escalation part and an expansion part.
Conditions
- Advanced Liver Cancer
Interventions
ABSK-011Drug
During the escalation part, the administration of oral ABSK-011 will be guided by "3+3"design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTTime frame: From the starting dosing of study drug to the end of Cycle 1 (each cycle is 28 days) in escalation Part
- Incidence and severity of AEs, AESIs and SAEsTime frame: 30 days after last administration, an average of one half year
- dose reduction or discontinuationTime frame: through study completion, an average of one half year
- physical examinations changes from baselineTime frame: through study completion, an average of one half year
- ECOG performance statusTime frame: through study completion, an average of one half year
- electrocardiograms (ECGs)Time frame: through study completion, an average of one half year
- echocardiograms changes from baselineTime frame: through study completion, an average of one half year
- vital signs changes from baselineTime frame: through study completion, an average of one half year
- vital signs changes from baselineTime frame: through study completion, an average of one half year
- vital signs changes from baselineTime frame: through study completion, an average of one half year
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Completed
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Recruiting
The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China · Withdrawn
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Completed
Sun Yat Sen Memorial Hospital
Guangzhou, Guangdong, China · Completed
Guangxi Zhuang Autonomous Region People's Hospital
Nanning, Guangxi, China · Completed
Weifang People's Hospital
Weifang, Hebei, China · Completed
Harbin Medical University Cancer Hospital
Haerbin, Heilongjiang, China · Recruiting
First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Completed
Henan Cancer Hospital
Zhengzhou, Henan, China · Completed
Hubei Cancer Hospital
Wuhan, Hubei, China · Completed
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Completed
Hunan Provincial People's Hospital
Changsha, Hunan, China · Withdrawn
Suzhou University Affiliated Second Hospital
Suzhou, Jiangsu, China · Completed
Tonghua Central Hospital
Tonghua, Jilin, China · Completed
Shengjing Hospital of China medical university
Shenyang, Liaoning, China · Completed
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Completed
Jinan Central Hospital
Jinan, Shandong, China · Completed
Linyi Cancer Hospital
Linyi, Shandong, China · Completed
The First Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China · Withdrawn
Mianyang Central Hospital
Mianyang, Sichuan, China · Recruiting
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
Ningbo, Zhejiang, China · Withdrawn
National Cheng Kung University Hospitals
Tainan, Taiwan · Completed
Nation Taiwan University Hospital
Taipei, Taiwan · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.